Myriad Genetics Lowers FY2026 Sales Guidance from $860.000M-$880.000M to $770.000M-$790.000M vs $863.568M Est
Myriad Genetics (NASDAQ: MYGN ) lowers FY2026 sales outlook from $860.000 million-$880.000 million to $770.000 million-$790.000 million vs $863.568 million estimate.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.